content: <HTML>
  <HEAD>
       <TITLE></TITLE>
  </HEAD>
  <BODY STYLE="font: 10pt Times New Roman, Times, Serif">
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>As filed with the Securities and Exchange Commission
  on February 21, 2025</B>&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Registration No. 333- </B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM S-8</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>THE SECURITIES ACT OF 1933</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>NeuroOne
  Medical Technologies Corporation</B></FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in its charter)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="border-bottom: black 1.5pt solid; padding: 0.25pt 0.75pt 0.75pt; text-align: center; width: 49%"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
      <TD STYLE="padding: 0.25pt 0.75pt 1.75pt; width: 2%">&nbsp;</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; padding: 0.25pt 0.75pt 0.75pt; text-align: center; width: 49%"><FONT STYLE="font-size: 10pt"><B>27-0863354</B></FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding: 0.25pt 0.75pt; text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of<BR>
  incorporation or organization)</FONT></TD>
      <TD STYLE="padding: 0.25pt 0.75pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt 0.75pt; text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer<BR>
  Identification No.)</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; padding: 0.25pt 0.75pt 0.75pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>7599 Anagram Dr., <BR>
  Eden Prairie, MN </B></FONT></TD>
      <TD STYLE="padding: 0.25pt 0.75pt 1.75pt; width: 2%">&nbsp;</TD>
      <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; padding: 0.25pt 0.75pt 0.75pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>55344</B></FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding: 0.25pt 0.75pt; text-align: center"><FONT STYLE="font-size: 10pt">(Address of principal executive offices) </FONT></TD>
      <TD STYLE="padding: 0.25pt 0.75pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt 0.75pt; text-align: center"><FONT STYLE="font-size: 10pt">(Zip code)</FONT></TD></TR>
    </TABLE>
  <P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NeuroOne Medical Technologies Corporation
  2025 Equity Incentive Plan</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Full title of the plan)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>David Rosa</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>President and Chief Executive Officer</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NeuroOne Medical Technologies Corporation</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>7599 Anagram Dr.,<BR>
  Eden Prairie, MN 55344</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>952-426-1383</b></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Name, address, and telephone number, including
  area code, of agent for service)</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Copy to:</b></p>
  
  <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><b>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Phillip D. Torrence, Esq.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Emily Johns, Esq.</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Honigman LLP</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>200 Ottawa Avenue NW, Suite 700</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Grand Rapids, Michigan 49503-2426</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(616) 649-1908</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is a large accelerated
  filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions
  of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo; &ldquo;smaller reporting company,&rdquo; and &ldquo;emerging
  growth company&rdquo; in Rule 12b-2 of the Exchange Act.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 20%"><FONT STYLE="font-size: 10pt">Large accelerated filer </FONT></TD>
      <TD STYLE="width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
      <TD STYLE="width: 20%"><FONT STYLE="font-size: 10pt">Accelerated filer </FONT></TD>
      <TD STYLE="width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD><FONT STYLE="font-size: 10pt">Non-accelerated filer </FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD>
      <TD><FONT STYLE="font-size: 10pt">Smaller reporting company </FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD COLSPAN="2">&nbsp;</TD>
      <TD><FONT STYLE="font-size: 10pt">Emerging growth company </FONT></TD>
      <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the registrant
  has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
  to Section 7(a)(2)(B) of the Securities Act. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT></P>
  
  <!-- Field: Page; Sequence: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>EXPLANATORY NOTE</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">On January 10, 2025, the Board of Directors of
  NeuroOne Medical Technologies Corporation, a Delaware corporation (the&nbsp;&ldquo;<B><I>Company&rdquo;</I></B>, the &ldquo;<B><I>Registrant</I></B>,<B><I>&rdquo;
  &ldquo;we</I></B>,<B><I>&rdquo; &ldquo;us</I></B>,<B><I>&rdquo; or &ldquo;our&rdquo;</I></B>) approved the NeuroOne 2025 Equity Incentive
  Plan (the &ldquo;<B><I>2025 Equity Incentive Plan</I></B>&rdquo;), subject to approval of the Company&rsquo;s stockholders. On February
  14, 2025, the Company&rsquo;s stockholders approved the 2025 Equity Incentive Plan. This Registration Statement on Form S-8 (this&nbsp;&ldquo;<B><I>Registration
  Statement&rdquo;</I></B>) is being filed with the U.S. Securities and Exchange Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;)
  to register the 3,000,000 shares of our common stock, par value $0.001 per share (the&nbsp;&ldquo;<B><I>Common Stock&rdquo;</I></B>) reserved
  under the 2025 Equity Incentive Plan, which provides for the grant of equity-based awards in the form of incentive stock options, nonstatutory
  stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of
  awards to employees, directors and consultants.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 2 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PART I </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
  </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75pt; text-indent: 35.25pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The information specified in Part I of Form
  S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act and the introductory
  note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants
  in the plan covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.</P>
  
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75pt 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75pt 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font-family: Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75pt 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75pt 0pt 0; text-align: center"><B>PART II</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Item 3.</B></FONT> <FONT STYLE="font-size: 10pt"><B>Incorporation of Documents by Reference. </B></FONT></P>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The following documents filed with the Commission
  by the Registrant are hereby incorporated by reference in this Registration Statement:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>our Annual Report on <a href="https://www.sec.gov/Archives/edgar/data/1500198/000121390024109524/ea0224514-10k_neuroon.htm">Form 10-K</A> for the fiscal year ended September 30, 2024, filed with the Commission on December 17, 2024 (including information specifically
  incorporated by reference herein from the Registrant&rsquo;s <a href="https://www.sec.gov/Archives/edgar/data/1500198/000121390025005016/ea0227444-02.htm">Proxy Statemen</A>t filed with the Commission on January 21, 2025);</TD></TR></TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>our Quarterly Report on <a href="https://www.sec.gov/Archives/edgar/data/1500198/000121390025012511/ea0230295-10q_neuroone.htm">Form 10-Q</A> for the quarter ended December 31, 2024, filed with the Commission on February 12, 2025.</TD></TR></TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(c)</TD><TD>our Current Reports on Form 8-K filed with the Commission on <a href="https://www.sec.gov/Archives/edgar/data/1500198/000121390024092879/ea0219340-8k_neuro.htm">October 31, 2024</A>, <a href="https://www.sec.gov/Archives/edgar/data/1500198/000121390024095934/ea0220503-8k_neuro.htm">November 8, 2024</A>, <a href="https://www.sec.gov/Archives/edgar/data/1500198/000121390024109529/ea0224944-8k_neuro.htm">December 17, 2024</A> with respect to Item 8.01, <a href="https://www.sec.gov/Archives/edgar/data/1500198/000121390025002728/ea0227395-8k_neuroone.htm">January 10, 2025</A>, <a href="https://www.sec.gov/Archives/edgar/data/1500198/000121390025010083/ea0229869-8k_neuroone.htm">February 4, 2025</A>, and <a href="https://www.sec.gov/Archives/edgar/data/1500198/000121390025014281/ea0231253-8k_neuroone.htm">February 14, 2025</A>, as amended on <A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390025015683/ea0231612-8ka1_neuroone.htm">February 20, 2025</A>.</TD></TR></TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(d)</TD><TD>the description of our Common Stock in our registration statement on&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000121390021028934/ea141508-8a12b_neuroone.htm">Form
  8-A</A>&nbsp;filed with the SEC on May 25, 2021 and as amended by any subsequent amendment or report filed for the purpose of updating
  such description.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 45.75pt">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, all documents the Registrant subsequently
  files pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, after the filing of this Registration
  Statement and prior to the filing of a post-effective amendment that indicates that all securities offered hereby have been sold or which
  deregisters all securities covered hereby then remaining unsold are incorporated by reference in this Registration Statement and are a
  part hereof from the date of filing of such documents. Notwithstanding anything herein, the Registrant is not incorporating by reference
  any information furnished under Item 2.02 or Item 7.01 of any Current Report on Form 8-K, unless, and to the extent, specified in any
  such Current Report on Form 8-K.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Any statement herein or contained in a document
  incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration
  Statement to the extent that a statement contained herein, or in any subsequently filed document, which also is or is deemed to be incorporated
  by reference herein, modifies or supersedes such prior statement. Any such statement so modified or superseded shall not be deemed, except
  as so modified or superseded, to constitute part of this Registration Statement.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Item 4.</B></FONT> <FONT STYLE="font-size: 10pt"><B>Description of Securities. </B></FONT></P>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Item 5.</B></FONT> <FONT STYLE="font-size: 10pt"><B>Interests of Named Experts and Counsel. </B></FONT></P>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Item 6.</B></FONT> <FONT STYLE="font-size: 10pt"><B>Indemnification of Directors and Officers. </B></FONT></P>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company is incorporated under the laws of the
  State of Delaware. Section 145 of the Delaware General Corporation Law provides that a Delaware corporation may indemnify any persons
  who were, are, or are threatened to be made, parties to any threatened, pending or completed action, suit or proceeding, whether civil,
  criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such
  person is or was an officer, director, employee or agent of such corporation, or is or was serving at the request of such corporation
  as an officer, director, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys&rsquo;
  fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action,
  suit or proceeding, provided that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed
  to the corporation&rsquo;s best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that
  his or her conduct was illegal. A Delaware corporation may indemnify any persons who were, are, or are threatened to be made, a party
  to any threatened, pending or completed action or suit by or in the right of the corporation by reason of the fact that such person is
  or was a director, officer, employee or agent of such corporation, or is or was serving at the request of such corporation as a director,
  officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys&rsquo; fees)
  actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit provided such person
  acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation&rsquo;s best interests except
  that no indemnification is permitted without judicial approval if the officer or director is adjudged to be liable to the corporation.
  Where an officer or director is successful on the merits or otherwise in the defense of any action referred to above, the corporation
  must indemnify him or her against the expenses (including attorneys&rsquo; fees) actually and reasonably incurred.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>
  
  <!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company&rsquo;s certificate of incorporation
  provides for the indemnification of its directors to the fullest extent permitted under the Delaware General Corporation Law. The Company&rsquo;s
  bylaws provide for the indemnification of its directors and officers to the fullest extent permitted under the Delaware General Corporation
  Law.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 102(b)(7) of the Delaware General Corporation
  Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable
  to the corporation or its stockholders for monetary damages for breach of fiduciary duties as a director, except for liability for any:</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;<FONT STYLE="font-family: Symbol"></FONT></TD><TD>transaction from which the director derives an improper personal benefit;</TD></TR><TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                                                                                        </TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;</TD></TR><TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                                                                                                                       </TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>unlawful payment of dividends or redemption of shares; or</TD></TR><TR STYLE="vertical-align: top">
  <TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                                                                        </TABLE>
  
  <TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
  <TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">&#9679;</TD><TD>breach of a director&rsquo;s duty of loyalty to the corporation or its stockholders.</TD></TR></TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company&rsquo;s certificate of incorporation
  includes such a provision. Under the Company&rsquo;s bylaws, expenses incurred by any director or officers in defending any such action,
  suit or proceeding in advance of its final disposition shall be paid by the Company upon delivery to it of an undertaking, by or on behalf
  of such director or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer is not
  entitled to be indemnified by the Company, as long as such undertaking remains required by the Delaware General Corporation Law.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Section 174 of the Delaware General Corporation
  Law provides, among other things, that a director who willfully or negligently approves of an unlawful payment of dividends or an unlawful
  stock purchase or redemption, may be held liable for such actions. A director who was either absent when the unlawful actions were approved
  or dissented at the time may avoid liability by causing his or her dissent to such actions to be entered in the books containing minutes
  of the meetings of the board of directors at the time such action occurred or immediately after such absent director receives notice of
  the unlawful acts.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">As permitted by the Delaware General Corporation
  Law, we have entered into indemnity agreements with each of our directors and executive officers, that require us to indemnify such persons
  against any and all expenses (including reasonable attorneys&rsquo; fees), witness fees, damages, judgments, fines, settlements and other
  amounts incurred (including expenses of a derivative action) in connection with any action, suit or proceeding, whether actual or threatened,
  to which any such person may be made a party by reason of the fact that such person is or was a director, an officer or an employee of
  the Company or any of its affiliated enterprises, provided that such person acted in good faith and in a manner such person reasonably
  believed to be in or not opposed to our best interests and, with respect to any criminal proceeding, had no reasonable cause to believe
  his or her conduct was unlawful. The indemnification agreements also set forth certain procedures that will apply in the event of a claim
  for indemnification thereunder.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company has an insurance policy that covers
  its officers and directors with respect to certain liabilities, including liabilities arising under the Securities Act or otherwise.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Item 7.</B></FONT> <FONT STYLE="font-size: 10pt"><B>Exemption from Registration Claimed. </B></FONT></P>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not Applicable.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>
  
  <!-- Field: Page; Sequence: 5; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 8. Exhibits. </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR>
      <TD STYLE="vertical-align: top; width: 8%; border-bottom: black 1.5pt solid; padding: 0.25pt 0.25pt 0.75pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Exhibit<BR>
   Number</B></FONT></TD>
      <TD STYLE="vertical-align: top; width: 1%; padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; width: 91%; border-bottom: black 1.5pt solid; padding: 0.25pt 0.25pt 0.75pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Description </B></FONT></TD></TR>
    <TR STYLE="vertical-align: top">
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt; font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1500198/000114420417034948/v470040_ex3-4.htm"><FONT STYLE="font-size: 10pt">Certificate of Incorporation of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.4 on the Registrant&rsquo;s Current Report on Form 8-K filed on June, 29, 2017).</FONT></A></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.2</FONT></TD>
      <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1500198/000121390021018989/ea138690ex3-1_neuroone.htm"><FONT STYLE="font-size: 10pt">Certificate of Amendment to Amended and Restated Certificate of Incorporation of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.1 on the Registrant&rsquo;s Current Report on Form 8-K filed on March 31, 2021)</FONT></A><FONT STYLE="font-size: 10pt">.</FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
    <TR STYLE="background-color: rgb(204,238,255)">
      <TD STYLE="vertical-align: top; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.3</FONT></TD>
      <TD STYLE="vertical-align: top; padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; padding: 0.25pt; font-size: 10pt"><A HREF="https://www.sec.gov/Archives/edgar/data/1500198/000121390024054782/ea020821701ex3-1_neuro.htm"><FONT STYLE="font-size: 10pt">Amended and Restated Bylaws of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.1 on the Registrant&rsquo;s Current Report on Form 8-K filed on June 21, 2024</FONT></A><FONT STYLE="font-size: 10pt">.</FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.4</FONT></TD>
      <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/0001500198/000121390025015683/ea023161201ex10-1_neuroone.htm">NeuroOne Medical Technologies Corporation 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 on the Registrant&rsquo;s Current Report on Form 8-K filed on February 20, 2025).</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.5</FONT></TD>
      <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/0001500198/000121390025015683/ea023161201ex10-2_neuroone.htm">NeuroOne Medical Technologies Corporation 2025 Equity Incentive Plan Form of Restricted Stock Unit Grant Agreement (incorporated by reference to Exhibit 10.2 on the Registrant&rsquo;s Current Report on Form 8-K filed on February 20, 2025).</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">4.6</FONT></TD>
      <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/0001500198/000121390025015683/ea023161201ex10-3_neuroone.htm">NeuroOne Medical Technologies Corporation 2025 Equity Incentive Plan Form of Option Grant Agreement (incorporated by reference to Exhibit 10.3 on the Registrant&rsquo;s Current Report on Form 8-K filed on February 20, 2025).</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">5.1*</FONT></TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="ea023170001ex5-1_neuroone.htm">Opinion of Honigman LLP.</A> </FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">23.1*</FONT></TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="ea023170001ex23-1_neuroone.htm">Consent of Baker Tilly US, LLP.</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">23.3*</FONT></TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="ea023170001ex5-1_neuroone.htm">Consent of Honigman LLP (included in its opinion filed as Exhibit 5.1 to this Registration Statement).</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">24.1*</FONT></TD>
      <TD STYLE="padding: 0.25pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="#a_001">Power of Attorney (included after the signature of the Registrant contained on the Signature Page of this Registration Statement).</A></FONT></TD></TR>
    <TR STYLE="vertical-align: top; background-color: White">
      <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
      <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">107*</FONT></TD>
      <TD STYLE="padding: 0.25pt; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt"><A HREF="ea023170001ex-fee_neuroone.htm">Filing Fee Table</A></FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 4%; padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">*</FONT></TD>
      <TD STYLE="padding: 0.25pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Filed herewith.</FONT></TD></TR>
    </TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 6; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-size: 10pt"><B>Item 9.</B></FONT> <FONT STYLE="font-size: 10pt"><B>Undertakings. </B></FONT></P>
  
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(a) </FONT></TD>
      <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">The Registrant hereby undertakes:</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in">&nbsp;</TD>
      <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
      <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.75in">&nbsp;</TD>
      <TD STYLE="width: 29px; font-size: 10pt"><FONT STYLE="font-size: 10pt">(i)</FONT></TD>
      <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">To include any prospectus required by Section 10(a)(3) of the Securities Act;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.75in">&nbsp;</TD>
      <TD STYLE="width: 29px; font-size: 10pt"><FONT STYLE="font-size: 10pt">(ii)</FONT></TD>
      <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Filing Fee Tables&rdquo; table in the effective Registration Statement;</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.75in">&nbsp;</TD>
      <TD STYLE="width: 29px; font-size: 10pt"><FONT STYLE="font-size: 10pt">(iii)</FONT></TD>
      <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;</FONT></TD></TR>
    </TABLE>
  
  <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.75in"><I>provided, however, </I>that paragraphs (a)(1)(i)
  and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained
  in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated
  by reference in the Registration Statement; and</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.9in">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in">&nbsp;</TD>
      <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
      <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offer thereof.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in">&nbsp;</TD>
      <TD STYLE="width: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
      <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
      <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">The Registrant hereby undertakes that, for the purpose of determining any liability under the Securities Act, each filing of the Registrant&rsquo;s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&rsquo;s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
    <TR STYLE="vertical-align: top">
      <TD STYLE="width: 0.5in; font-size: 10pt"><FONT STYLE="font-size: 10pt">(c)</FONT></TD>
      <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</FONT></TD></TR>
    </TABLE>
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>
  
  <!-- Field: Page; Sequence: 7; Value: 1 -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
      <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><A NAME="a_001"></A><B>SIGNATURES</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Act of 1933, as amended,
  the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has
  duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Eden
  Prairie, State of Minnesota, on this 21<SUP>st</SUP> day of February, 2025.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: top">
      <TD>&nbsp;</TD>
      <TD COLSPAN="2" STYLE="font-size: 10pt">NeuroOne Medical Technologies Corporation</TD></TR>
    <TR>
      <TD>&nbsp;</TD>
      <TD COLSPAN="2">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top; width: 60%">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom; width: 4%; font-size: 10pt">By:</TD>
      <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: top; width: 36%; font-size: 10pt">/s/ David Rosa</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">David A. Rosa</TD></TR>
    <TR>
      <TD STYLE="vertical-align: top">&nbsp;</TD>
      <TD STYLE="vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top">Chief Executive Officer</TD></TR>
    </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>POWER OF ATTORNEY </B></P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Each person whose signature appears below constitutes and appoints
  David A. Rosa and Ronald McClurg, or either of them, as his true and lawful attorneys-in-fact and agents, with full power of substitution
  and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any or all amendments (including post-effective
  amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection
  therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, full power and authority to do
  and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes
  as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their
  substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Pursuant to the requirements of the Securities Act of 1933, this Registration
  Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
  
  <TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
    <TR STYLE="vertical-align: bottom">
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap; width: 36%"><B>Signature</B></TD>
      <TD STYLE="padding-bottom: 1.5pt; text-align: center; width: 1%"><B>&nbsp;</B></TD>
      <td style="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap; width: 39%"><B>Title</B></TD>
      <TD STYLE="padding-bottom: 1.5pt; text-align: center; width: 1%"><B>&nbsp;</B></TD>
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: center; white-space: nowrap; width: 23%"><B>Date</B></TD></TR>
    <TR>
      <TD STYLE="text-align: left">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD>
      <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; vertical-align: top">/s/ David A. Rosa </TD>
      <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
      <td style="text-align: left; vertical-align: top; font-size: 10pt">Chief Executive Officer </TD>
      <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">February 21, 2025</TD></TR>
    <TR>
      <TD STYLE="text-align: left; vertical-align: top">David A. Rosa</TD>
      <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
      <td style="text-align: left; vertical-align: top; font-size: 10pt">(Principal Executive Officer) and a Director</TD>
      <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="text-align: left; vertical-align: top; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
      <td style="text-align: left; vertical-align: top; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; vertical-align: top; font-size: 10pt">/s/ Ronald McClurg</TD>
      <TD STYLE="text-align: center; vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
      <td style="text-align: left; vertical-align: top; font-size: 10pt">Chief Financial Officer</TD>
      <TD STYLE="text-align: center; vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">February 21, 2025</TD></TR>
    <TR>
      <TD STYLE="text-align: left; vertical-align: top; font-size: 10pt">Ronald McClurg</TD>
      <TD STYLE="text-align: center; vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
      <td style="text-align: left; vertical-align: top; font-size: 10pt">(Principal Financial and Accounting Officer)</TD>
      <TD STYLE="text-align: center; vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="text-align: left; vertical-align: top; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
      <td style="text-align: left; vertical-align: top; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; vertical-align: top">/s/ Paul Buckman </TD>
      <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
      <td style="text-align: left; vertical-align: top; font-size: 10pt">Director</TD>
      <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">February 21, 2025</TD></TR>
    <TR>
      <TD STYLE="text-align: left; vertical-align: top">Paul Buckman</TD>
      <TD STYLE="text-align: center; vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
      <td style="text-align: left; vertical-align: top; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
      <td style="text-align: left; vertical-align: top; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; vertical-align: top">/s/ Jeffrey Mathiesen </TD>
      <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
      <td style="text-align: left; vertical-align: top; font-size: 10pt">Director</TD>
      <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">February 21, 2025</TD></TR>
    <TR>
      <TD STYLE="text-align: left; vertical-align: top">Jeffrey Mathiesen</TD>
      <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
      <td style="text-align: left; vertical-align: top; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="text-align: left; vertical-align: top">&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
      <td style="text-align: left; vertical-align: top; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
    <TR>
      <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; vertical-align: top">/s/ Edward Andrle </TD>
      <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
      <td style="text-align: left; vertical-align: top; font-size: 10pt">Director</TD>
      <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">February 21, 2025</TD></TR>
    <TR>
      <TD STYLE="text-align: left; vertical-align: top">Edward Andrle</TD>
      <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
      <td style="text-align: left; vertical-align: top; font-size: 10pt">&nbsp;</TD>
      <TD STYLE="text-align: center; vertical-align: bottom">&nbsp;</TD>
      <TD STYLE="vertical-align: top; font-size: 10pt; text-align: center">&nbsp;</TD></TR>
    </TABLE>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75pt; text-align: center">&nbsp;</P>
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75pt; text-align: center"></P>
  
  <!-- Field: Page; Sequence: 8; Options: Last -->
      <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
      <!-- Field: /Page -->
  
  <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.75pt; text-align: center">&nbsp;</P>
  
  </BODY>
  </HTML>
metadata_documents: [{"type": "S-8", "sequence": "1", "filename": "ea0231700-s8_neuroone.htm", "description": "REGISTRATION STATEMENT", "secsgml_size_bytes": 63596}]
metadata_filer: {"company-data": {"conformed-name": "NEUROONE MEDICAL TECHNOLOGIES Corp", "cik": "0001500198", "assigned-sic": "3841", "organization-name": "08 Industrial Applications and Services", "irs-number": "270863354", "state-of-incorporation": "DE", "fiscal-year-end": "0930"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-285129", "film-number": "25652092"}, "business-address": {"street1": "7599 ANAGRAM DR", "city": "EDEN PRAIRIE", "state": "MN", "zip": "55344", "phone": "(952) 426-1383"}, "mail-address": {"street1": "7599 ANAGRAM DR", "city": "EDEN PRAIRIE", "state": "MN", "zip": "55344"}, "former-company": {"former-conformed-name": "Original Source Entertainment, Inc.", "date-changed": "20100830"}}
text: As filed with the Securities and Exchange Commission
  on February 21, 2025
  Registration No. 333-
  UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  Washington, D.C. 20549
  FORM S-8
  REGISTRATION STATEMENT
  UNDER
  THE SECURITIES ACT OF 1933
  NeuroOne
  Medical Technologies Corporation
  (Exact name of registrant as specified in its charter)
  Delaware
  27-0863354
  (State or other jurisdiction of
  incorporation or organization)
  (I.R.S. Employer
  Identification No.)
  7599 Anagram Dr.,
  Eden Prairie, MN
  55344
  (Address of principal executive offices)
  (Zip code)
  NeuroOne Medical Technologies Corporation
  2025 Equity Incentive Plan
  (Full title of the plan)
  David Rosa
  President and Chief Executive Officer
  NeuroOne Medical Technologies Corporation
  7599 Anagram Dr.,
  Eden Prairie, MN 55344
  952-426-1383
  (Name, address, and telephone number, including
  area code, of agent for service)
  Copy to:
  Phillip D. Torrence, Esq.
  Emily Johns, Esq.
  Honigman LLP
  200 Ottawa Avenue NW, Suite 700
  Grand Rapids, Michigan 49503-2426
  (616) 649-1908
  Indicate by check mark whether the registrant is a large accelerated
  filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions
  of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging
  growth company" in Rule 12b-2 of the Exchange Act.
  Large accelerated filer
  ☐
  Accelerated filer
  ☐
  Non-accelerated filer
  ☒
  Smaller reporting company
  ☒
  Emerging growth company
  ☐
  If an emerging growth company, indicate by check mark if the registrant
  has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
  to Section 7(a)(2)(B) of the Securities Act.
  ☐
  EXPLANATORY NOTE
  On January 10, 2025, the Board of Directors of
  NeuroOne Medical Technologies Corporation, a Delaware corporation (the "
  Company"
  , the "
  Registrant
  ,
  "
  "we
  ,
  " "us
  ,
  " or "our"
  ) approved the NeuroOne 2025 Equity Incentive
  Plan (the "
  2025 Equity Incentive Plan
  "), subject to approval of the Company's stockholders. On February
  14, 2025, the Company's stockholders approved the 2025 Equity Incentive Plan. This Registration Statement on Form S-8 (this "
  Registration
  Statement"
  ) is being filed with the U.S. Securities and Exchange Commission (the "
  Commission
  ")
  to register the 3,000,000 shares of our common stock, par value $0.001 per share (the "
  Common Stock"
  ) reserved
  under the 2025 Equity Incentive Plan, which provides for the grant of equity-based awards in the form of incentive stock options, nonstatutory
  stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of
  awards to employees, directors and consultants.
  PART I
  INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
  The information specified in Part I of Form
  S-8 is omitted from this Registration Statement in accordance with the provisions of Rule 428 under the Securities Act and the introductory
  note to Part I of Form S-8. The documents containing the information specified in Part I of Form S-8 will be delivered to the participants
  in the plan covered by this Registration Statement as specified by Rule 428(b)(1) under the Securities Act.
  1
  PART II
  INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
  Item 3.
  Incorporation of Documents by Reference.
  The following documents filed with the Commission
  by the Registrant are hereby incorporated by reference in this Registration Statement:
  (a)
  our Annual Report on
  Form 10-K
  for the fiscal year ended September 30, 2024, filed with the Commission on December 17, 2024 (including information specifically
  incorporated by reference herein from the Registrant's
  Proxy Statemen
  t filed with the Commission on January 21, 2025);
  (b)
  our Quarterly Report on
  Form 10-Q
  for the quarter ended December 31, 2024, filed with the Commission on February 12, 2025.
  (c)
  our Current Reports on Form 8-K filed with the Commission on
  October 31, 2024
  ,
  November 8, 2024
  ,
  December 17, 2024
  with respect to Item 8.01,
  January 10, 2025
  ,
  February 4, 2025
  , and
  February 14, 2025
  , as amended on
  February 20, 2025
  .
  (d)
  the description of our Common Stock in our registration statement on
  Form
  8-A
  filed with the SEC on May 25, 2021 and as amended by any subsequent amendment or report filed for the purpose of updating
  such description.
  In addition, all documents the Registrant subsequently
  files pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, after the filing of this Registration
  Statement and prior to the filing of a post-effective amendment that indicates that all securities offered hereby have been sold or which
  deregisters all securities covered hereby then remaining unsold are incorporated by reference in this Registration Statement and are a
  part hereof from the date of filing of such documents. Notwithstanding anything herein, the Registrant is not incorporating by reference
  any information furnished under Item 2.02 or Item 7.01 of any Current Report on Form 8-K, unless, and to the extent, specified in any
  such Current Report on Form 8-K.
  Any statement herein or contained in a document
  incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration
  Statement to the extent that a statement contained herein, or in any subsequently filed document, which also is or is deemed to be incorporated
  by reference herein, modifies or supersedes such prior statement. Any such statement so modified or superseded shall not be deemed, except
  as so modified or superseded, to constitute part of this Registration Statement.
  Item 4.
  Description of Securities.
  Not applicable.
  Item 5.
  Interests of Named Experts and Counsel.
  Not applicable.
  Item 6.
  Indemnification of Directors and Officers.
  The Company is incorporated under the laws of the
  State of Delaware. Section 145 of the Delaware General Corporation Law provides that a Delaware corporation may indemnify any persons
  who were, are, or are threatened to be made, parties to any threatened, pending or completed action, suit or proceeding, whether civil,
  criminal, administrative or investigative (other than an action by or in the right of such corporation), by reason of the fact that such
  person is or was an officer, director, employee or agent of such corporation, or is or was serving at the request of such corporation
  as an officer, director, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys'
  fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action,
  suit or proceeding, provided that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed
  to the corporation's best interests and, with respect to any criminal action or proceeding, had no reasonable cause to believe that
  his or her conduct was illegal. A Delaware corporation may indemnify any persons who were, are, or are threatened to be made, a party
  to any threatened, pending or completed action or suit by or in the right of the corporation by reason of the fact that such person is
  or was a director, officer, employee or agent of such corporation, or is or was serving at the request of such corporation as a director,
  officer, employee or agent of another corporation or enterprise. The indemnity may include expenses (including attorneys' fees)
  actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit provided such person
  acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the corporation's best interests except
  that no indemnification is permitted without judicial approval if the officer or director is adjudged to be liable to the corporation.
  Where an officer or director is successful on the merits or otherwise in the defense of any action referred to above, the corporation
  must indemnify him or her against the expenses (including attorneys' fees) actually and reasonably incurred.
  II-
  1
  The Company's certificate of incorporation
  provides for the indemnification of its directors to the fullest extent permitted under the Delaware General Corporation Law. The Company's
  bylaws provide for the indemnification of its directors and officers to the fullest extent permitted under the Delaware General Corporation
  Law.
  Section 102(b)(7) of the Delaware General Corporation
  Law permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally liable
  to the corporation or its stockholders for monetary damages for breach of fiduciary duties as a director, except for liability for any:
  ●
  transaction from which the director derives an improper personal benefit;
  ●
  act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
  ●
  unlawful payment of dividends or redemption of shares; or
  ●
  breach of a director's duty of loyalty to the corporation or its stockholders.
  The Company's certificate of incorporation
  includes such a provision. Under the Company's bylaws, expenses incurred by any director or officers in defending any such action,
  suit or proceeding in advance of its final disposition shall be paid by the Company upon delivery to it of an undertaking, by or on behalf
  of such director or officer, to repay all amounts so advanced if it shall ultimately be determined that such director or officer is not
  entitled to be indemnified by the Company, as long as such undertaking remains required by the Delaware General Corporation Law.
  Section 174 of the Delaware General Corporation
  Law provides, among other things, that a director who willfully or negligently approves of an unlawful payment of dividends or an unlawful
  stock purchase or redemption, may be held liable for such actions. A director who was either absent when the unlawful actions were approved
  or dissented at the time may avoid liability by causing his or her dissent to such actions to be entered in the books containing minutes
  of the meetings of the board of directors at the time such action occurred or immediately after such absent director receives notice of
  the unlawful acts.
  As permitted by the Delaware General Corporation
  Law, we have entered into indemnity agreements with each of our directors and executive officers, that require us to indemnify such persons
  against any and all expenses (including reasonable attorneys' fees), witness fees, damages, judgments, fines, settlements and other
  amounts incurred (including expenses of a derivative action) in connection with any action, suit or proceeding, whether actual or threatened,
  to which any such person may be made a party by reason of the fact that such person is or was a director, an officer or an employee of
  the Company or any of its affiliated enterprises, provided that such person acted in good faith and in a manner such person reasonably
  believed to be in or not opposed to our best interests and, with respect to any criminal proceeding, had no reasonable cause to believe
  his or her conduct was unlawful. The indemnification agreements also set forth certain procedures that will apply in the event of a claim
  for indemnification thereunder.
  The Company has an insurance policy that covers
  its officers and directors with respect to certain liabilities, including liabilities arising under the Securities Act or otherwise.
  Item 7.
  Exemption from Registration Claimed.
  Not Applicable.
  II-
  2
  Item 8. Exhibits.
  Exhibit
  Number
  Description
  4.1
  Certificate of Incorporation of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.4 on the Registrant's Current Report on Form 8-K filed on June, 29, 2017).
  4.2
  Certificate of Amendment to Amended and Restated Certificate of Incorporation of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.1 on the Registrant's Current Report on Form 8-K filed on March 31, 2021)
  .
  4.3
  Amended and Restated Bylaws of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.1 on the Registrant's Current Report on Form 8-K filed on June 21, 2024
  .
  4.4
  NeuroOne Medical Technologies Corporation 2025 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 on the Registrant's Current Report on Form 8-K filed on February 20, 2025).
  4.5
  NeuroOne Medical Technologies Corporation 2025 Equity Incentive Plan Form of Restricted Stock Unit Grant Agreement (incorporated by reference to Exhibit 10.2 on the Registrant's Current Report on Form 8-K filed on February 20, 2025).
  4.6
  NeuroOne Medical Technologies Corporation 2025 Equity Incentive Plan Form of Option Grant Agreement (incorporated by reference to Exhibit 10.3 on the Registrant's Current Report on Form 8-K filed on February 20, 2025).
  5.1*
  Opinion of Honigman LLP.
  23.1*
  Consent of Baker Tilly US, LLP.
  23.3*
  Consent of Honigman LLP (included in its opinion filed as Exhibit 5.1 to this Registration Statement).
  24.1*
  Power of Attorney (included after the signature of the Registrant contained on the Signature Page of this Registration Statement).
  107*
  Filing Fee Table
  *
  Filed herewith.
  II-
  3
  Item 9.
  Undertakings.
  (a)
  The Registrant hereby undertakes:
  (1)
  To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:
  (i)
  To include any prospectus required by Section 10(a)(3) of the Securities Act;
  (ii)
  To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the "Calculation of Filing Fee Tables" table in the effective Registration Statement;
  (iii)
  to include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;
  provided, however,
  that paragraphs (a)(1)(i)
  and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained
  in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or 15(d) of the Exchange Act that are incorporated
  by reference in the Registration Statement; and
  (2)
  That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offer thereof.
  (3)
  To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.
  (b)
  The Registrant hereby undertakes that, for the purpose of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.
  (c)
  Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.
  II-
  4
  SIGNATURES
  Pursuant to the requirements of the Securities Act of 1933, as amended,
  the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has
  duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Eden
  Prairie, State of Minnesota, on this 21
  st
  day of February, 2025.
  NeuroOne Medical Technologies Corporation
  By:
  /s/ David Rosa
  David A. Rosa
  Chief Executive Officer
  POWER OF ATTORNEY
  Each person whose signature appears below constitutes and appoints
  David A. Rosa and Ronald McClurg, or either of them, as his true and lawful attorneys-in-fact and agents, with full power of substitution
  and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any or all amendments (including post-effective
  amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection
  therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, full power and authority to do
  and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes
  as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their
  substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
  Pursuant to the requirements of the Securities Act of 1933, this Registration
  Statement on Form S-8 has been signed by the following persons in the capacities and on the dates indicated.
  Signature
  Title
  Date
  /s/ David A. Rosa
  Chief Executive Officer
  February 21, 2025
  David A. Rosa
  (Principal Executive Officer) and a Director
  /s/ Ronald McClurg
  Chief Financial Officer
  February 21, 2025
  Ronald McClurg
  (Principal Financial and Accounting Officer)
  /s/ Paul Buckman
  Director
  February 21, 2025
  Paul Buckman
  /s/ Jeffrey Mathiesen
  Director
  February 21, 2025
  Jeffrey Mathiesen
  /s/ Edward Andrle
  Director
  February 21, 2025
  Edward Andrle
  II-
  5